Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS 株式レポート

時価総額:US$18.1m

Marinus Pharmaceuticals 将来の成長

Future 基準チェック /26

Marinus Pharmaceuticals is forecast to grow earnings and revenue by 62.3% and 38.9% per annum respectively while EPS is expected to grow by 68.7% per annum.

主要情報

62.3%

収益成長率

68.7%

EPS成長率

Pharmaceuticals 収益成長23.7%
収益成長率38.9%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日25 Oct 2024

今後の成長に関する最新情報

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Recent updates

A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Sep 20
A Piece Of The Puzzle Missing From Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Share Price

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Apr 16
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 08
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Dec 22
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Sep 22
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Jun 12
Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

May 16
Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Oct 12
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Marinus Pharmaceuticals: Positive News Flow Of Note

Sep 22

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Aug 29

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Jul 28

Revisiting Marinus Pharmaceuticals

May 05

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27
Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption

Feb 28

業績と収益の成長予測

NasdaqGM:MRNS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202677-34892838
12/31/202550-69-77-7711
12/31/202436-116-103-10011
6/30/202430-149-121-120N/A
3/31/202428-145-114-114N/A
12/31/202331-141-118-118N/A
9/30/202331-134-113-113N/A
6/30/202326-29-119-117N/A
3/31/202322-35-128-127N/A
12/31/202225-20-115-113N/A
9/30/202220-14-115-113N/A
6/30/202228-105-80-78N/A
3/31/202228-91-69-67N/A
12/31/202115-99-58-55N/A
9/30/202115-88-52-50N/A
6/30/20215-84-71-70N/A
3/31/20214-76-63-63N/A
12/31/20202-76-61-61N/A
9/30/20200-74-61-61N/A
6/30/2020N/A-72-58-58N/A
3/31/2020N/A-69-51-51N/A
12/31/2019N/A-54-49-49N/A
9/30/2019N/A-49-42-42N/A
6/30/2019N/A-46-37-36N/A
3/31/2019N/A-43-34-33N/A
12/31/2018N/A-37-28-28N/A
9/30/2018N/A-31-23-23N/A
6/30/2018N/A-24-20-19N/A
3/31/2018N/A-19N/A-18N/A
12/31/2017N/A-19N/A-19N/A
9/30/2017N/A-20N/A-20N/A
6/30/2017N/A-22N/A-24N/A
3/31/2017N/A-27N/A-26N/A
12/31/2016N/A-29N/A-25N/A
9/30/2016N/A-30N/A-24N/A
6/30/2016N/A-29N/A-23N/A
3/31/2016N/A-25N/A-22N/A
12/31/2015N/A-25N/A-20N/A
9/30/2015N/A-21N/A-17N/A
6/30/2015N/A-18N/A-14N/A
3/31/2015N/A-17N/A-11N/A
12/31/2014N/A-13N/A-9N/A
9/30/2014N/A-12N/A-10N/A
6/30/2014N/A-12N/A-8N/A
3/31/2014N/A-11N/A-7N/A

アナリストによる今後の成長予測

収入対貯蓄率: MRNS is forecast to remain unprofitable over the next 3 years.

収益対市場: MRNS is forecast to remain unprofitable over the next 3 years.

高成長収益: MRNS is forecast to remain unprofitable over the next 3 years.

収益対市場: MRNS's revenue (38.9% per year) is forecast to grow faster than the US market (8.9% per year).

高い収益成長: MRNS's revenue (38.9% per year) is forecast to grow faster than 20% per year.


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: Insufficient data to determine if MRNS's Return on Equity is forecast to be high in 3 years time


成長企業の発掘